Delta-Fly Pharma, Inc.
4598
Rank in Stocks
#30253
Delta-Fly Pharma, Inc., established in Tokushima, Japan, in 2010, is a... Delta-Fly Pharma, Inc., established in Tokushima, Japan, in 2010, is a biotechnology company focused on the development of innovative oncology drugs. Their comprehensive pipeline includes several drug candidates targeting various cancers. DFP-10917 is currently undergoing Phase III clinical evaluation in the United States and Phase I in Japan for relapsed/refractory acute myeloid leukemia. Another significant compound, DFP-14323, is in Phase III trials for lung cancer. The firm is also advancing DFP-17729 through Phase I/II studies for solid tumors. Furthermore, DFP-11207 has successfully completed its Phase I clinical trial for pancreatic cancer. For hematologic malignancies, DFP-14927 is in Phase I, while DFP-10825 is in preclinical development, targeting gastric and ovarian cancers.
Share Price
$0.38770232
Last synced: 2026-11-13
Market Cap
$5.42M
Change (1 day)
3.21%
Change (1 year)
-89.02%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Delta-Fly Pharma, Inc. (4598)
Category
Healthcare
Operating Margin for Delta-Fly Pharma, Inc. (4598)
Operating Margin as of November 2026 TTM: 0.00%
According to Delta-Fly Pharma, Inc.'s latest financial reports, its current operating margin (TTM) is 0.00%. At the end of 2025 the company had an operating margin of 0.00%.
Operating Margin history for Delta-Fly Pharma, Inc. from 2017 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 0.00% | 0.00% |
| 2025 | 0.00% | 0.00% |
| 2024 | 0.00% | 0.00% |
| 2023 | 0.00% | -100.00% |
| 2022 | -320.49% | 12.82% |
| 2021 | -284.08% | -81.61% |
| 2020 | -1,545.00% | 0.00% |
| 2019 | 0.00% | -100.00% |
| 2018 | -162.55% | -546.08% |
| 2017 | 36.44% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| -195.39% | - |
US
|
|
| 33.87% | - |
US
|
|
| -116.04% | - |
US
|
|
| 25.57% | - |
AU
|
|
| 31.23% | - |
BE
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Delta-Fly Pharma, Inc.'s operating margin
What was Delta-Fly Pharma, Inc.'s operating margin in 2025?
In 2025, Delta-Fly Pharma, Inc.'s operating margin was 0.00%, compared with 0.00% in 2024.
How has Delta-Fly Pharma, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Delta-Fly Pharma, Inc.'s operating margin was highest in 2025 (0.00%) and lowest in 2020 (-1,545.00%).
How does Delta-Fly Pharma, Inc.'s operating margin compare with similar companies?
Delta-Fly Pharma, Inc.'s operating margin (0.00%) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 33.87%.